Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Recurrent, Refractory, or High Risk Leukemias Clear all
Completed Phase 2 Interventional Results available

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

NCT00278161
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Pegfilgrastim, Rituximab, Cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Jul 23, 2026, 8:00 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

NCT01118013
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Jul 23, 2026, 8:00 PM EDT
Completed Phase 1 Interventional Results available

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

NCT02484391
View directory record Official record
Conditions
Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia
Interventions
6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation, Mitoxantrone Hydrochloride
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 8:00 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

NCT00509691
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique
Biological · Genetic · Other
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 23, 2026, 8:00 PM EDT
Completed Phase 2 Interventional Results available

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

NCT04487106
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Azacitidine, Trametinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 23, 2026, 8:00 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia

NCT01656031
View directory record Official record
Conditions
Leukemia
Interventions
clofarabine, cytarabine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jul 23, 2026, 8:00 PM EDT
Completed Phase 1 Interventional

GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia

NCT00459212
View directory record Official record
Conditions
Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
GTI-2040, pharmacological study, laboratory biomarker analysis
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Jul 23, 2026, 8:00 PM EDT
Recruiting Phase 2 Interventional

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT05672251
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Loncastuximab Tesirine, Mosunetuzumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 8:00 PM EDT
Recruiting Phase 2 Interventional

Personalized NK Cell Therapy in CBT

NCT02727803
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia With Variant MLL Translocations, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chemotherapy-Related Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Gene Mutation, Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Rituximab, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Biological · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 8:00 PM EDT
Terminated Phase 1Phase 2 Interventional

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT04550442
View directory record Official record
Conditions
Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome
Interventions
Azacitidine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 8:00 PM EDT
Completed Phase 1Phase 2 Interventional

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia

NCT01842672
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma/Leukemia
Interventions
Clofarabine, Mitoxantrone
Drug
Lead sponsor
New York Medical College
Other
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Valhalla, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Jul 23, 2026, 8:00 PM EDT
Terminated Phase 1 Interventional

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

NCT00112619
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Jul 23, 2026, 8:00 PM EDT
Active, not recruiting Not applicable Interventional Results available

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

NCT02670525
View directory record Official record
Conditions
Recurrent, Refractory, or High Risk Leukemias, Matched Targeted Therapy
Interventions
Leukemia Profiling
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 23, 2026, 8:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

NCT02392572
View directory record Official record
Conditions
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Akt/ERK Inhibitor ONC201, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 23, 2026, 8:00 PM EDT
Terminated Phase 1 Interventional

Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias

NCT00852709
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Disorders, Acute Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia
Interventions
Clofarabine, Cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Jul 23, 2026, 8:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

NCT00002663
View directory record Official record
Conditions
EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Interventions
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Biological
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
Not listed
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jul 23, 2026, 8:00 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT01191190
View directory record Official record
Conditions
CLL
Interventions
Ofatumumab/HDMP
Drug
Lead sponsor
Januario Castro, M.D.
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Jul 23, 2026, 8:00 PM EDT
Suspended Phase 1Phase 2 Interventional

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT04278768
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Emavusertib, Venetoclax
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 8:00 PM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00003397
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, sargramostim, carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, gemcitabine hydrochloride, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jul 23, 2026, 8:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

NCT06523556
View directory record Official record
Conditions
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm
Interventions
Axatilimab, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Survey Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 8:00 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

NCT00582816
View directory record Official record
Conditions
Leukemia, Solid Tumors
Interventions
Clinimacs Cell Separation System, conditioning chemotherapy, DLI
Device · Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
6 Months to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Jul 23, 2026, 8:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT05010122
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine and Cedazuridine, Gilteritinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 8:00 PM EDT
Terminated Phase 1 Interventional

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT05961839
View directory record Official record
Conditions
Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
Interventions
SGR-2921
Drug
Lead sponsor
Schrödinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Denver, Colorado • Fairway, Kansas • Buffalo, New York + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 23, 2026, 8:00 PM EDT
Completed Phase 1 Interventional

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01757639
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Ipilimumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
9
States / cities
New Haven, Connecticut • North Haven, Connecticut • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Jul 23, 2026, 8:00 PM EDT